register

Medical

Medicines Australia and MTAA welcome Government support for harmonisation of clinical trials

Health Industry Hub | July 3, 2020 |

Medical News: Medicines Australia and Medical Technology Association of Australia (MTAA) welcome the announcement from the Minister for Health, the Hon Greg Hunt MP, during his CEDA address that he will be asking the National Cabinet to expedite “a one stop shop” for ethics approval of clinical trials in Australia.

Medicines Australia said while improvements to R&D tax incentive policy settings also remain essential, harmonisation of the arrangements surrounding clinical trials nationwide are vital if we are to increase investment in this critical area and ensure a health-led economic recovery from the COVID-19 pandemic. This reform will mean a healthier Australia along with investment in Australian jobs and economic growth.

“The medical technology industry has long advocated for national harmonisation of clinical trials and welcomes Minister Hunt’s announcement of a one-stop-shop for ethics approval,” said Ian Burgess, MTAA CEO.

“Local clinical trials provide Australian patients with early access to innovative medical devices and treatments and place Australia at the forefront of global advancements of medical technology.

“An active medical device clinical trial environment in Australia will provide local expertise to support Australian start-ups and research groups, accelerating their growth and retaining capability and expertise within Australia,” Mr Burgess said.

As governments, state and federal, consider the steps required to ensure a healthy Australia as we emerge from the worst of the COVID-19 crisis, the innovative pharmaceutical companies represented by Medicines Australia are playing their part in contributing to the global effort to develop a vaccine and improve Australia’s prospects of its being delivered to our citizens in a timely and equitable fashion.

Minister Hunt’s announcement, if adopted by National Cabinet, would enhance the attraction of Australia as a destination for clinical trials for all innovative medicines and therapies. Premiers and Chief Ministers can take action to deliver consistency within and between jurisdictions. Their action will decrease complexity and increase speed of commencement of clinical trials and encourage new trials to be initiated, generating further jobs, economic growth and social improvements.

With our general success so far regarding COVID-19, Australia is well-placed to be ‘open for business’ on clinical trials at a time when many other parts of the globe have had to halt trials due to hospitals and clinical staff being overwhelmed.

Medicines Australia and MTAA look forward to working with Minister Hunt, the Department of Health and State and Territory Governments on this important initiative.


Human Resources

Medtronic HR Director deep dives into shifting workplaces and leadership trends: International HR Day

Medtronic HR Director deep dives into shifting workplaces and leadership trends: International HR Day

Health Industry Hub | May 20, 2024 |

People & Culture: Coinciding with International HR Day, Karen Newell, Senior HR Director for ANZ at Medtronic, joined Health Industry […]

More


News & Trends - MedTech & Diagnostics

Aussie medtech reveals new data on next-gen pulsed field ablation system for atrial fibrillation

Aussie medtech reveals new data on next-gen pulsed field ablation system for atrial fibrillation

Health Industry Hub | May 20, 2024 |

MedTech & Diagnostics News: An Australian-based medtech company announced promising results from the first-in-human study for its pulsed field ablation […]

More


News & Trends - MedTech & Diagnostics

Federal budget delivers 'mixed news' for radiologists

Federal budget delivers ‘mixed news’ for radiologists

Health Industry Hub | May 20, 2024 |

MedTech & Diagnostics News: The Royal College of Australian and New Zealand Radiologists (RANZCR) and the Interventional Radiology Society of […]

More


News & Trends - Pharmaceuticals

AstraZeneca, BMS and Noxopharm address findings of inquiry report into rare cancers

AstraZeneca, BMS and Noxopharm address findings of inquiry report into rare cancers

Health Industry Hub | May 20, 2024 |

Pharma News: The Senate Community Affairs References Committee has released its inquiry report into Equitable access to diagnosis and treatment […]

More


This content is copyright protected. Please subscribe to gain access.